Literature DB >> 21749289

Structural diversity repertoire of gene silencing small interfering RNAs.

Chan Il Chang1, Helena Andrade Kim, Pooja Dua, Soyoun Kim, Chiang J Li, Dong-ki Lee.   

Abstract

Since the discovery of double-stranded (ds) RNA-mediated RNA interference (RNAi) phenomenon in Caenorhabditis elegans, specific gene silencing based upon RNAi mechanism has become a novel biomedical tool that has extended our understanding of cell biology and opened the door to an innovative class of therapeutic agents. To silence genes in mammalian cells, short dsRNA referred to as small interfering RNA (siRNA) is used as an RNAi trigger to avoid nonspecific interferon responses induced by long dsRNAs. An early structure-activity relationship study performed in Drosophila melanogaster embryonic extract suggested the existence of strict siRNA structural design rules to achieve optimal gene silencing. These rules include the presence of a 3' overhang, a fixed duplex length, and structural symmetry, which defined the structure of a classical siRNA. However, several recent studies performed in mammalian cells have hinted that the gene silencing siRNA structure could be much more flexible than that originally proposed. Moreover, many of the nonclassical siRNA structural variants reported improved features over the classical siRNAs, including increased potency, reduced nonspecific responses, and enhanced cellular delivery. In this review, we summarize the recent progress in the development of gene silencing siRNA structural variants and discuss these in light of the flexibility of the RNAi machinery in mammalian cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21749289      PMCID: PMC3198623          DOI: 10.1089/nat.2011.0286

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  48 in total

1.  Asymmetry in the assembly of the RNAi enzyme complex.

Authors:  Dianne S Schwarz; György Hutvágner; Tingting Du; Zuoshang Xu; Neil Aronin; Phillip D Zamore
Journal:  Cell       Date:  2003-10-17       Impact factor: 41.582

2.  Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain.

Authors:  Jin-Biao Ma; Keqiong Ye; Dinshaw J Patel
Journal:  Nature       Date:  2004-05-20       Impact factor: 49.962

3.  RNA interference: human genes hit the big screen.

Authors:  Andrew Fraser
Journal:  Nature       Date:  2004-03-25       Impact factor: 49.962

4.  A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells.

Authors:  Joao Trindade Marques; Thalie Devosse; Die Wang; Maryam Zamanian-Daryoush; Paul Serbinowski; Rune Hartmann; Takashi Fujita; Mark A Behlke; Bryan R G Williams
Journal:  Nat Biotechnol       Date:  2006-04-30       Impact factor: 54.908

5.  Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy.

Authors:  Dong-Ho Kim; Mark A Behlke; Scott D Rose; Mi-Sook Chang; Sangdun Choi; John J Rossi
Journal:  Nat Biotechnol       Date:  2004-12-26       Impact factor: 54.908

6.  Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways.

Authors:  Dirk Grimm; Konrad L Streetz; Catherine L Jopling; Theresa A Storm; Kusum Pandey; Corrine R Davis; Patricia Marion; Felix Salazar; Mark A Kay
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

Review 7.  How cells respond to interferons.

Authors:  G R Stark; I M Kerr; B R Williams; R H Silverman; R D Schreiber
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

8.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

9.  Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing.

Authors:  Jens Harborth; Sayda M Elbashir; Kim Vandenburgh; Heiko Manninga; Stephen A Scaringe; Klaus Weber; Thomas Tuschl
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2003-04

10.  Functional polarity is introduced by Dicer processing of short substrate RNAs.

Authors:  Scott D Rose; Dong-Ho Kim; Mohammed Amarzguioui; Jeremy D Heidel; Michael A Collingwood; Mark E Davis; John J Rossi; Mark A Behlke
Journal:  Nucleic Acids Res       Date:  2005-07-26       Impact factor: 16.971

View more
  9 in total

Review 1.  Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS.

Authors:  Manjunath N Swamy; Haoquan Wu; Premlata Shankar
Journal:  Adv Drug Deliv Rev       Date:  2016-03-21       Impact factor: 15.470

2.  Selection and optimization of asymmetric siRNA targeting the human c-MET gene.

Authors:  Seul-gi Jo; Sun Woo Hong; Jae Wook Yoo; Chang Han Lee; Sera Kim; Soyoun Kim; Dong-ki Lee
Journal:  Mol Cells       Date:  2011-11-03       Impact factor: 5.034

3.  Hypoxia-inducible factor-1α and its role in the proliferation of retinoblastoma cells.

Authors:  Bruno F Fernandes; James Coates; Alexandre N Odashiro; Carlos Quezada; Aimee Huynh; Patricia R Odashiro; Macanori Odashiro; Miguel N Burnier
Journal:  Pathol Oncol Res       Date:  2013-12-14       Impact factor: 3.201

Review 4.  Progress toward in vivo use of siRNAs-II.

Authors:  Garrett R Rettig; Mark A Behlke
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

5.  RNA interference-mediated simultaneous silencing of four genes using cross-shaped RNA.

Authors:  Tae Yeon Lee; Chan Il Chang; Dooyoung Lee; Sun Woo Hong; Chanseok Shin; Chiang J Li; Soyoun Kim; Dirk Haussecker; Dong-Ki Lee
Journal:  Mol Cells       Date:  2013-04-04       Impact factor: 5.034

6.  Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes.

Authors:  Yuya Nishimura; Hiroaki Mieda; Jun Ishii; Chiaki Ogino; Toshinobu Fujiwara; Akihiko Kondo
Journal:  J Nanobiotechnology       Date:  2013-06-24       Impact factor: 10.435

7.  An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases.

Authors:  Agnieszka Fiszer; Marta Olejniczak; Pawel M Switonski; Joanna P Wroblewska; Joanna Wisniewska-Kruk; Agnieszka Mykowska; Wlodzimierz J Krzyzosiak
Journal:  BMC Mol Biol       Date:  2012-03-07       Impact factor: 2.946

8.  The Business of RNAi Therapeutics in 2012.

Authors:  Dirk Haussecker
Journal:  Mol Ther Nucleic Acids       Date:  2012-02-07       Impact factor: 10.183

9.  In vitro antiviral activity of circular triple helix forming oligonucleotide RNA towards Feline Infectious Peritonitis virus replication.

Authors:  Oi Kuan Choong; Parvaneh Mehrbod; Bimo Ario Tejo; Abdul Rahman Omar
Journal:  Biomed Res Int       Date:  2014-02-20       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.